Ann-Christin Ostwaldt1, Michal Rozanski2,3, Tabea Schaefer2, Martin Ebinger2,3, Gerhard J Jungehülsing4, Kersten Villringer2, Jochen B Fiebach2. 1. Academic Neuroradiology, Center for Stroke Research Berlin (CSB), Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. aostwaldt@mgh.harvard.edu. 2. Academic Neuroradiology, Center for Stroke Research Berlin (CSB), Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. 3. Department of Neurology, Charité Universitätsmedizin, Charitéplatz 1, 10117, Berlin, Germany. 4. Jüdisches Krankenhaus Berlin, Stiftung des Bürgerlichen Rechts, Heinz-Galinski-Straße 1, 13347, Berlin, Germany.
Abstract
OBJECTIVE: The hyperintense acute reperfusion marker (HARM) on fluid-attenuated inversion recovery (FLAIR) images is associated with blood-brain barrier (BBB) permeability changes. The aim of this study was to examine the influence of contrast agent dosage on HARM incidence in acute ischaemic stroke patients. METHODS: We prospectively included 529 acute ischaemic stroke patients (204 females, median age 71 years). Patients underwent a first stroke-MRI within 24 hours from symptom onset and had a follow-up on day 2. The contrast agent Gadobutrol was administered to the patients for perfusion imaging or MR angiography. The total dosage was calculated as ml/kg body weight and ranged between 0.04 and 0.31 mmol/kg on the first examination. The incidence of HARM was evaluated on day 2 FLAIR images. RESULTS: HARM was detected in 97 patients (18.3%). HARM incidence increased significantly with increasing dosages of Gadobutrol. Also, HARM positive patients were significantly older. HARM was not an independent predictor of worse clinical outcome, and we did not find an association with increase risk of haemorrhagic transformation. CONCLUSIONS: A higher dosage of Gadobutrol in acute stroke patients on initial MRI is associated with increased HARM incidence on follow-up. MRI studies on BBB should therefore standardize contrast agent dosages. KEY POINTS: • Hyperintense acute reperfusion marker on MRI indicates blood-brain barrier disruption. • This observational study on stroke patients characterizes HARM. • Incidence depends on contrast agent dosage on the previous day. • HARM is also associated with older age and poor kidney function. • Interpretation of HARM must take dosage into consideration.
OBJECTIVE: The hyperintense acute reperfusion marker (HARM) on fluid-attenuated inversion recovery (FLAIR) images is associated with blood-brain barrier (BBB) permeability changes. The aim of this study was to examine the influence of contrast agent dosage on HARM incidence in acute ischaemic strokepatients. METHODS: We prospectively included 529 acute ischaemic strokepatients (204 females, median age 71 years). Patients underwent a first stroke-MRI within 24 hours from symptom onset and had a follow-up on day 2. The contrast agent Gadobutrol was administered to the patients for perfusion imaging or MR angiography. The total dosage was calculated as ml/kg body weight and ranged between 0.04 and 0.31 mmol/kg on the first examination. The incidence of HARM was evaluated on day 2 FLAIR images. RESULTS: HARM was detected in 97 patients (18.3%). HARM incidence increased significantly with increasing dosages of Gadobutrol. Also, HARM positive patients were significantly older. HARM was not an independent predictor of worse clinical outcome, and we did not find an association with increase risk of haemorrhagic transformation. CONCLUSIONS: A higher dosage of Gadobutrol in acute strokepatients on initial MRI is associated with increased HARM incidence on follow-up. MRI studies on BBB should therefore standardize contrast agent dosages. KEY POINTS: • Hyperintense acute reperfusion marker on MRI indicates blood-brain barrier disruption. • This observational study on strokepatients characterizes HARM. • Incidence depends on contrast agent dosage on the previous day. • HARM is also associated with older age and poor kidney function. • Interpretation of HARM must take dosage into consideration.
Entities:
Keywords:
Acute stroke; Blood-Brain Barrier; Dosage; Gadolinium; Magnetic Resonance Imaging
Authors: Michal Rozanski; Martin Ebinger; Wolf U Schmidt; Benjamin Hotter; Sandra Pittl; Peter U Heuschmann; Jan G Jungehuelsing; Jochen B Fiebach Journal: Eur Radiol Date: 2010-07-21 Impact factor: 5.315
Authors: Lawrence L Latour; Dong-Wha Kang; Mustapha A Ezzeddine; Julio A Chalela; Steven Warach Journal: Ann Neurol Date: 2004-10 Impact factor: 10.422
Authors: Benjamin Hotter; Sandra Pittl; Martin Ebinger; Gabriele Oepen; Kati Jegzentis; Kohsuke Kudo; Michal Rozanski; Wolf U Schmidt; Peter Brunecker; Chao Xu; Peter Martus; Matthias Endres; Gerhard J Jungehülsing; Arno Villringer; Jochen B Fiebach Journal: BMC Neurol Date: 2009-12-08 Impact factor: 2.474
Authors: Linda L Lee; Hnin H Aung; Dennis W Wilson; Steven E Anderson; John C Rutledge; Jennifer M Rutkowsky Journal: Am J Physiol Cell Physiol Date: 2017-01-11 Impact factor: 4.249
Authors: Anke Wouters; Lauranne Scheldeman; Patrick Dupont; Bastian Cheng; Martin Ebinger; Märit Jensen; Matthias Endres; Christian Gerloff; Keith W Muir; Norbert Nighoghossian; Salvador Pedraza; Claus Z Simonsen; Florent Boutitie; Vincent Thijs; Götz Thomalla; Jochen Fiebach; Robin Lemmens Journal: Eur Stroke J Date: 2021-06-12
Authors: Sara Bernardo-Castro; João André Sousa; Ana Brás; Carla Cecília; Bruno Rodrigues; Luciano Almendra; Cristina Machado; Gustavo Santo; Fernando Silva; Lino Ferreira; Isabel Santana; João Sargento-Freitas Journal: Front Neurol Date: 2020-12-09 Impact factor: 4.003
Authors: Luigi Francesco Saccaro; Imen Bekri; Maxime De Malherbe; Intissar Hmida; Fernando Pico Journal: BMC Neurol Date: 2022-04-14 Impact factor: 2.474
Authors: Whitney M Freeze; Merel van der Thiel; Jeroen de Bresser; Catharina J M Klijn; Ellis S van Etten; Jacobus F A Jansen; Louise van der Weerd; Heidi I L Jacobs; Walter H Backes; Susanne J van Veluw Journal: Neuroimage Clin Date: 2020-10-02 Impact factor: 4.881